Thomas A. Lanz

3.4k total citations · 1 hit paper
43 papers, 2.2k citations indexed

About

Thomas A. Lanz is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Physiology. According to data from OpenAlex, Thomas A. Lanz has authored 43 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 13 papers in Cellular and Molecular Neuroscience and 12 papers in Physiology. Recurrent topics in Thomas A. Lanz's work include Alzheimer's disease research and treatments (10 papers), Virus-based gene therapy research (6 papers) and Drug Transport and Resistance Mechanisms (6 papers). Thomas A. Lanz is often cited by papers focused on Alzheimer's disease research and treatments (10 papers), Virus-based gene therapy research (6 papers) and Drug Transport and Resistance Mechanisms (6 papers). Thomas A. Lanz collaborates with scholars based in United States, United Kingdom and Switzerland. Thomas A. Lanz's co-authors include Kalpana Merchant, Robin J. Kleiman, Veronica Reinhart, Susan E. Bove, Dmitri Volfson, Joel B. Schachter, David A. Lewis, Wade J. Adams, Roberto Di Maio and Matthew T. Keeney and has published in prestigious journals such as Proceedings of the National Academy of Sciences, PLoS ONE and Journal of Molecular Biology.

In The Last Decade

Thomas A. Lanz

39 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

LRRK2 activation in idiopathic Parkinson’s disease

2018 385 citations Roberto Di Maio, Eric K. Hoffman et al. Science Translational Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas A. Lanz United States	24	923	811	515	397	332	43	2.2k
Mario M. Dorostkar Germany	29	1.0k 1.1×	742 0.9×	1.0k 1.9×	189 0.5×	204 0.6×	65	2.4k
Jiro Takano Japan	22	1.1k 1.2×	1.2k 1.5×	766 1.5×	277 0.7×	273 0.8×	26	2.5k
Joshua M. Shulman United States	20	1.2k 1.3×	1.3k 1.6×	644 1.3×	366 0.9×	241 0.7×	36	2.4k
Juha Laurén Finland	12	1.6k 1.8×	1.2k 1.5×	1.0k 2.0×	226 0.6×	217 0.7×	16	2.8k
Shaoli Che United States	28	1.2k 1.3×	1.3k 1.6×	649 1.3×	277 0.7×	166 0.5×	39	2.5k
Masayasu Okochi Japan	30	1.5k 1.6×	1.6k 2.0×	894 1.7×	422 1.1×	1.1k 3.2×	70	3.4k
Bernadette Allinquant France	25	1.6k 1.8×	1.4k 1.8×	882 1.7×	244 0.6×	135 0.4×	74	3.3k
Ji Won Um South Korea	29	1.8k 2.0×	1.1k 1.4×	1.4k 2.7×	208 0.5×	399 1.2×	65	3.2k
Uwe Konietzko Switzerland	22	1.4k 1.5×	1.9k 2.3×	1.0k 2.0×	520 1.3×	103 0.3×	37	3.2k
Thomas Fath Australia	24	1.1k 1.2×	887 1.1×	545 1.1×	161 0.4×	381 1.1×	59	2.4k

Countries citing papers authored by Thomas A. Lanz

Since Specialization

Citations

This map shows the geographic impact of Thomas A. Lanz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas A. Lanz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas A. Lanz more than expected).

Fields of papers citing papers by Thomas A. Lanz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas A. Lanz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas A. Lanz. The network helps show where Thomas A. Lanz may publish in the future.

Co-authorship network of co-authors of Thomas A. Lanz

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas A. Lanz. A scholar is included among the top collaborators of Thomas A. Lanz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas A. Lanz. Thomas A. Lanz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hamy, Anne‐Sophie, Juliana Antero, Thomas A. Lanz, et al.. (2025). Changes in Physical Activity, Heart Rate, and Sleep Measured by Activity Trackers During the COVID-19 Pandemic Across 34 Countries: Retrospective Analysis. Journal of Medical Internet Research. 27. e68199–e68199.

Lanz, Thomas A., Klemens Ruprecht, Jens Göpfert, et al.. (2025). Longitudinal evaluation of serum neurofilament light levels in normal healthy volunteers: defining a threshold of concern. Journal of Neurology. 272(8). 512–512.

Qiu, Luping, Steven W. Kumpf, Elias M. Oziolor, et al.. (2025). In vitro NIH3T3 mouse embryonic fibroblast cell model does not predict AAV2 or AAVdj-mediated cell transformation. Toxicology and Applied Pharmacology. 495. 117229–117229. 2 indexed citations

Brimble, Mark A., Jane Owens, Laurence O. Whiteley, et al.. (2024). Single cell and TCR analysis of immune cells from AAV gene therapy-dosed Duchenne muscular dystrophy patients. Molecular Therapy — Methods & Clinical Development. 32(4). 101349–101349. 4 indexed citations

Kumpf, Steven W., et al.. (2024). Comparison and cross-validation of long-read and short-read target-enrichment sequencing methods to assess AAV vector integration into host genome. Molecular Therapy — Methods & Clinical Development. 32(4). 101352–101352. 1 indexed citations

Oziolor, Elias M., Steven W. Kumpf, Mark Gosink, et al.. (2023). Comparing molecular and computational approaches for detecting viral integration of AAV gene therapy constructs. Molecular Therapy — Methods & Clinical Development. 29. 395–405. 14 indexed citations

Reinhart, Veronica, Thomas A. Lanz, Mark L. Weber, et al.. (2021). Schizophrenia-associated SLC39A8 polymorphism is a loss-of-function allele altering glutamate receptor and innate immune signaling. Translational Psychiatry. 11(1). 136–136. 19 indexed citations

Malik, Ruchi, Thomas A. Lanz, Mark L. Weber, et al.. (2020). GluN2D-mediated excitatory drive onto medial prefrontal cortical PV+ fast-spiking inhibitory interneurons. PLoS ONE. 15(6). e0233895–e0233895. 24 indexed citations

Padmanabhan, Shalini, Thomas A. Lanz, Donal Gorman, et al.. (2020). An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson’s Disease and G2019S LRRK2 Cohorts. Journal of Parkinson s Disease. 10(2). 623–629. 29 indexed citations

10.

Lanz, Thomas A., et al.. (2020). 3’Pool-seq: an optimized cost-efficient and scalable method of whole-transcriptome gene expression profiling. BMC Genomics. 21(1). 64–64. 11 indexed citations

11.

Maio, Roberto Di, Eric K. Hoffman, Emily M. Rocha, et al.. (2018). LRRK2 activation in idiopathic Parkinson’s disease. Science Translational Medicine. 10(451). 385 indexed citations breakdown →

12.

Piro, Justin R., Georgette L. Suidan, Jie Quan, et al.. (2018). Inhibition of 2-AG hydrolysis differentially regulates blood brain barrier permeability after injury. Journal of Neuroinflammation. 15(1). 142–142. 37 indexed citations

13.

Reinhart, Veronica, Susan E. Bove, Dmitri Volfson, et al.. (2015). Evaluation of TrkB and BDNF transcripts in prefrontal cortex, hippocampus, and striatum from subjects with schizophrenia, bipolar disorder, and major depressive disorder. Neurobiology of Disease. 77. 220–227. 117 indexed citations

14.

Chekler, Eugene L. Piatnitski, Thomas A. Lanz, R. Aldrin Denny, et al.. (2015). Transcriptional Profiling of a Selective CREB Binding Protein Bromodomain Inhibitor Highlights Therapeutic Opportunities. Chemistry & Biology. 22(12). 1588–1596. 41 indexed citations

15.

Lanz, Thomas A., et al.. (2015). STEP Levels Are Unchanged in Pre-Frontal Cortex and Associative Striatum in Post-Mortem Human Brain Samples from Subjects with Schizophrenia, Bipolar Disorder and Major Depressive Disorder. PLoS ONE. 10(3). e0121744–e0121744. 43 indexed citations

16.

Lanz, Thomas A., Christopher T. Salatto, M. Marconi, et al.. (2007). Peripheral elevation of IGF-1 fails to alter Aβ clearance in multiple in vivo models. Biochemical Pharmacology. 75(5). 1093–1103. 29 indexed citations

17.

Lanz, Thomas A., Gregory J. Fici, & Kalpana Merchant. (2004). Lack of Specific Amyloid-β(1-42) Suppression by Nonsteroidal Anti-Inflammatory Drugs in Young, Plaque-Free Tg2576 Mice and in Guinea Pig Neuronal Cultures. Journal of Pharmacology and Experimental Therapeutics. 312(1). 399–406. 53 indexed citations

18.

Lanz, Thomas A., et al.. (2004). Studies of Aβ Pharmacodynamics in the Brain, Cerebrospinal Fluid, and Plasma in Young (Plaque-Free) Tg2576 Mice Using the γ-Secretase Inhibitor N2-[(2 S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-N1-[(7 S)-5-methyl-6-oxo-6,7-dihydro-5 H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575). Journal of Pharmacology and Experimental Therapeutics. 309(1). 49–55. 113 indexed citations

19.

Lanz, Thomas A., et al.. (2003). The γ-Secretase Inhibitor N-[N-(3,5-Difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl Ester Reduces Aβ Levels in Vivo in Plasma and Cerebrospinal Fluid in Young (Plaque-Free) and Aged (Plaque-Bearing) Tg2576 Mice. Journal of Pharmacology and Experimental Therapeutics. 305(3). 864–871. 118 indexed citations

20.

Kraly, F. Scott, et al.. (1998). H2 histaminergic control of inhibition of eating induced by intragastric NaCl in rats. Physiology & Behavior. 65(1). 105–113. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact